Navigation Links
PLC Systems Files IDE Supplement to Begin Pivotal Study of RenalGuard(TM) and Provides Update on Planned Development Timeline
Date:2/15/2008

FRANKLIN, Mass., Feb. 15 /PRNewswire-FirstCall/ -- PLC Systems Inc. (Amex: PLC) announced today that it has submitted an Investigational Device Exemption (IDE) supplement with the U.S. Food & Drug Administration (FDA) for its RenalGuard Therapy(TM) and RenalGuard System(TM). This supplement seeks approval to move to a pivotal trial to study the effectiveness of the Company's RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy.

According to the current timetable, PLC expects to commence the pivotal trial after receipt of FDA approval. Contrast-Induced Nephropathy, or CIN, is a major and growing problem due to the increasing number of older patients, diabetics and patients with pre-existing renal impairment -- all of whose conditions make them at risk for CIN when they require interventional procedures that use radiographic contrast media. This study is designed as an adaptive, randomized control trial, with potentially up to 30 sites in the U.S. Enrollment in the trial is expected to last through 2009, and to include at least 250 patients. PLC is continuing discussions with FDA on metrics and endpoints to be used in the study, in addition to sample size and other aspects of the study design, which is currently expected to cost approximately $3 million.

This trial design builds upon the successful completion of the company's pilot trial in December, a study that was designed to preliminarily evaluate safety associated with Renal Guard Therapy and RenalGuard System. A total of 23 patients were enrolled in the study.

Mark R. Tauscher, President and Chief Executive Officer of PLC, said, "We are very pleased with the continued progress on our RenalGuard studies. Submitting the IDE for t
'/>"/>

SOURCE PLC Systems Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. New study shows extent of harmful human influences on global ecosystems
2. Microsoft Announces the Amalga Family of Health Enterprise Systems
3. Thomson Healthcares Clinical Xpert Navigator Tops KLAS Annual Performance Ranking in Mobile Data Systems for Sixth Consecutive Year
4. Harman/Becker Automotive Systems Completes Initial Deployments of Visiprise Integrated Manufacturing Execution
5. Merit Medical Systems Announces Earnings Release Date/Time and Conference Call Information for the Year Ended December 31, 2007
6. Microsoft Dynamics CRM 4.0 Users now can include Telephony and Call Recording features by adding ConversationPRO(TM) from VoiceGate, a Division of IgeaCare Systems Inc.
7. Keystone Human Services Acquires Impact Systems, Inc.
8. IDC Digital radiography systems Ranked #1 for third consecutive quarter
9. OxySure(R) Systems, Inc. Named to 2008 Worlds Best Technologies (WBT) List For its Unique, Safe and Easy to Use Portable Emergency Oxygen Generator, Which Provides Medical Oxygen Without the Need for Compressed Tanks
10. Cardicas C-Port Anastomosis Systems for Coronary Artery Bypass Graft Procedures to be Used to Train Cardiothoracic Surgeons at Society of Thoracic Surgeons (STS) University
11. Sonian Introduces the Most Affordable, Reliable and Scaleable Email Archiving Solution for All Messaging Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)..., July 25 /PRNewswire/ -- BeaconEquity.com announc...ng news today., Investors can view all of the dai...conEquity.com/m , Today,s Trade Alerts include: D...rook Pharmaceuticals Inc. (Nasdaq: MBRK ), NovaMe... ), Affymetrix Inc. (Nasdaq: AFFX ) and,Abaxis In...
(Date:7/25/2008)...Relationship Based on Significant Improvements in ... MDdatacor, Inc., a leader in health,care quality ...s, today,announced it has entered into a long-term...ort Wellmark,s Collaboration on Quality(SM) Incent...tion between Wellmark and,primary care clinicians ...
(Date:7/25/2008)...AD, Calif., July 25 /PRNewswire/ -- AutoGenomics, ...ion statement on Form S-1 with the,Securities and ...al public,offering of shares of its common stock. ..., all of which are expected to be offered by,AutoG...g, have not yet been,determined., J.P. Morgan Sec...
(Date:7/25/2008)... Whether you are an Olympian, Profe... there are Five Things You Need to Know about Hydr...C. Spine and Sports Center , ...- America,s premier athletes are heading to Beijin...g and sacrifice in the hopes of capturing an Olymp...
Breaking Medicine News(10 mins):Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 4Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 5
...ry Centre in Wishaw is recovering at home in North....coli O157 infection. The Craigneuk Nursery Cent...s have been reported. A NHS Lanarkshire, spokesm...ild's age or sex, said all staff and parents of ch...
...the 25 year mark and this year has been heralded a...ss to lifesaving treatments last year even in deve...eported declining HIV infection rates. However Bil...nce in Toronto this week said that current trends ...
...h is needed to to fill in the gaps in HIV vaccine ...tut Pasteur//, France, at the 16th International A... Barré-Sinoussi there have been 85 HIV vaccine tri... Yet we are no closer to finding out whether a pro...
... soft drinks of two multinational giants till a re...overnment for testing, Chief Minister Buddhadeb Bh...aken only after we receive the report," Bhattachar...sharp contrast to Kerala, another communist-ruled ...
Other Medicine News:Health News:Need for Change in Social Norms to Prevent Spread of HIV 2Health News:Need for Change in Social Norms to Prevent Spread of HIV 3
(Date:7/23/2008)...re/ -- The following was,released by the U.S. Depa...ber Smith, and Members of the Committee.,Thank you...ppeared before this Committee almost six months ag...alented and dedicated professionals,at the Justice...come to,appreciate that much more deeply their ser...
(Date:7/23/2008)...-- Dendreon Corporation,(Nasdaq: DNDN ) today ann...ring Committee (IDMC) to review in October 2008 th... the Company,s Phase 3 IMPACT (IMmunotherapy,for P...902B) clinical trial,of PROVENGE(R) (sipuleucel-T)... cellular immunotherapy for the treatment of advan...
(Date:7/22/2008)...in Medical, a leading innovator,of physiological m...tered,the clinical testing phase with its breakthr...ion. Today,s most common application for this,tech...l blood oxygenation,in the brain -- cerebral oxime...oing clinical study at the,Duke University Medical...
(Date:7/22/2008)...a Exhibits Excellent Drug-Like ...tiation of Phase II Clinical Trials -, RESEARCH T... BioPharma,Inc., a clinical stage company develop...diseases of the central nervous system, today anno...M) into Phase II trials for the,treatment of depre...
Breaking Medicine Technology:Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Nicotine addiction slashed in test of new cigarette smoking strategy 6279 1Nicotine addiction slashed in test of new cigarette smoking strategy 6279 2Nicotine addiction slashed in test of new cigarette smoking strategy 6279 3Synaptics SecurePad 28TM 29 Selected as CES Innovations 2008 Design and Engineering Award Honoree 1208 1Synaptics SecurePad 28TM 29 Selected as CES Innovations 2008 Design and Engineering Award Honoree 1208 2Synaptics SecurePad 28TM 29 Selected as CES Innovations 2008 Design and Engineering Award Honoree 1208 3Plastic Surgery Complications and Deaths are Rare Despite Highly Publicized Death of Donda West 6273 1Plastic Surgery Complications and Deaths are Rare Despite Highly Publicized Death of Donda West 6273 2Plastic Surgery Complications and Deaths are Rare Despite Highly Publicized Death of Donda West 6273 3Fortune 500 Executive Elected to AMA Board of Trustees 6267 1Fortune 500 Executive Elected to AMA Board of Trustees 6267 2
...%; mso-hyphenate: none">,BUDAPEST, Hungary, June, ...ands of patients with cancer from suffering,unnece...gress of,the European Association for Palliative C...ted whether this first in class novel,formulation ...duration of effect, mirroring the breakthrough pai...
...IMPAX Laboratories,Inc. (OTC:IPXL) today announce...company,s compound, IPX054, a combined immediate-,...oduct to be,marketed as VADOVA(TM), were presented...onal Congress of Parkinson,s Disease and,Movement ... poster,presentations will be available in the Inv...
Other Medicine Technology:Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 2Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 3Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 4Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 5Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 6IMPAX Presents at Movement Disorder Society's 11th International,Congress of Parkinson's Disease and Movement Disorders 2IMPAX Presents at Movement Disorder Society's 11th International,Congress of Parkinson's Disease and Movement Disorders 3IMPAX Presents at Movement Disorder Society's 11th International,Congress of Parkinson's Disease and Movement Disorders 4
... FoamWrap ACTION Elbow Wrap replaces messy taping ..., and others experiencing epicondylitis. Preferred...nd non-bulky fit. Two overlay straps allow you to ...m lining holds the Elbow Wrap comfortably in place...
The Bledsoe Extender Arm Brace is designed to handle post-op elbow arthroscopy, severe elbow strains and ligament trauma. The Bledsoe Extender Arm Brace should be used when limited R.O.M. or locked c
...s controlled stretch ankle support helps reduce sw... of motion. It is easy to apply - it slips on lik...es. It features bilateral spiral stays that move ...nd stability. This is an excellent support for li...
...s lightweight ankle splint may be used for either ... It is effective in stabilizing the ankle joint f...removal. The rigid pre-bent metal stays are adjus... The stays also help the splint control rotational...
Medicine Products: